Product Name :
NBI-31772 hydrate
Description:
NBI-31772 hydrate is a potent inhibitor of interaction between insulin-like growth factor (IGF) and IGF-binding proteins (IGFBPs). NBI-31772 hydrate is also a nonpeptide ligand that releases bioactive IGF-I from the IGF-I/IGFBP-3 complex (Kis=1-24 nM for all six human subtypes). Anxiolytic and antidepressant-like effects.
CAS:
Molecular Weight:
372.80
Formula:
C68H58N4O35
Chemical Name:
tetrakis(1-(3,4-dihydroxybenzoyl)-6,7-dihydroxyisoquinoline-3-carboxylic acid) heptahydrate
Smiles :
O.O.O.O.O.O.O.OC(=O)C1=CC2=CC(O)=C(O)C=C2C(=N1)C(=O)C1=CC(O)=C(O)C=C1.OC(=O)C1=CC2=CC(O)=C(O)C=C2C(=N1)C(=O)C1=CC(O)=C(O)C=C1.OC(=O)C1=CC2=CC(O)=C(O)C=C2C(=N1)C(=O)C1=CC(O)=C(O)C=C1.OC(=O)C1=CC2=CC(O)=C(O)C=C2C(=N1)C(=O)C1=CC(O)=C(O)C=C1
InChiKey:
VPUOQTDTRRNXBR-UHFFFAOYSA-N
InChi :
InChI=1S/4C17H11NO7.7H2O/c4*19-11-2-1-7(4-12(11)20)16(23)15-9-6-14(22)13(21)5-8(9)3-10(18-15)17(24)25;;;;;;;/h4*1-6,19-22H,(H,24,25);7*1H2
Purity:
≥98% (or refer to the Certificate of Analysis)
Shipping Condition:
Shipped under ambient temperature as non-hazardous chemical or refer to Certificate of Analysis
Storage Condition :
Dry, dark and -20 oC for 1 year or refer to the Certificate of Analysis.
Shelf Life:
≥12 months if stored properly.
Stock Solution Storage:
0 – 4 oC for 1 month or refer to the Certificate of Analysis.
Additional information:
NBI-31772 hydrate is a potent inhibitor of interaction between insulin-like growth factor (IGF) and IGF-binding proteins (IGFBPs).{{Dexrazoxane} web|{Dexrazoxane} Purity & Documentation|{Dexrazoxane} Purity|{Dexrazoxane} custom synthesis|{Dexrazoxane} Autophagy} NBI-31772 hydrate is also a nonpeptide ligand that releases bioactive IGF-I from the IGF-I/IGFBP-3 complex (Kis=1-24 nM for all six human subtypes).{{Quinine} site|{Quinine} Flavivirus|{Quinine} Biological Activity|{Quinine} In Vitro|{Quinine} custom synthesis|{Quinine} Epigenetic Reader Domain} Anxiolytic and antidepressant-like effects.PMID:24605203 |Product information|Molecular Weight: 372.80|Formula: C68H58N4O35|Chemical Name: tetrakis(1-(3,4-dihydroxybenzoyl)-6,7-dihydroxyisoquinoline-3-carboxylic acid) heptahydrate|Smiles: O.O.O.O.O.O.O.OC(=O)C1=CC2=CC(O)=C(O)C=C2C(=N1)C(=O)C1=CC(O)=C(O)C=C1.OC(=O)C1=CC2=CC(O)=C(O)C=C2C(=N1)C(=O)C1=CC(O)=C(O)C=C1.OC(=O)C1=CC2=CC(O)=C(O)C=C2C(=N1)C(=O)C1=CC(O)=C(O)C=C1.OC(=O)C1=CC2=CC(O)=C(O)C=C2C(=N1)C(=O)C1=CC(O)=C(O)C=C1|InChiKey: VPUOQTDTRRNXBR-UHFFFAOYSA-N|InChi: InChI=1S/4C17H11NO7.7H2O/c4*19-11-2-1-7(4-12(11)20)16(23)15-9-6-14(22)13(21)5-8(9)3-10(18-15)17(24)25;;;;;;;/h4*1-6,19-22H,(H,24,25);7*1H2|Technical Data|Appearance: Solid Power|Purity: ≥98% (or refer to the Certificate of Analysis)|Shipping Condition: Shipped under ambient temperature as non-hazardous chemical or refer to Certificate of Analysis|Storage Condition: Dry, dark and -20 oC for 1 year or refer to the Certificate of Analysis.|Shelf Life: ≥12 months if stored properly.|Stock Solution Storage: 0 – 4 oC for 1 month or refer to the Certificate of Analysis.|Drug Formulation: To be determined|HS Tariff Code: 382200|How to use|In Vivo:|NBI-31772 (5-100 μg; icv; immediately or at 1, 2, or, 3 hours after MCAO) at the time of ischemia onset also dose-dependently reduced infarct size, and the highest dose (100 μg) significantly reduced both total and cortical infarct volume.|Products are for research use only. Not for human use.|
